| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | DiabetOmics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Element Science | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $115.4M | Series C-3 | 3/3/2020 | $163.35 | $296.95M | $1.63 | Deerfield Healthcare, Qiming Venture Partners, Cormorant Asset Management, Invus Opportunities, Third Rock Ventures, GV | ||||
 | Harbor Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $384.26M | Series A-4-4 | 2/20/2026 | $45M | $436.68M | $0.71 | Undisclosed Investors | ||||
 | KRY | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | KSQ Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $417.49M | Series D-1 | 10/24/2025 | $160.03M | $486.98M | $2.65 | Undisclosed Investors | ||||
 | Latent | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $94.02M | Series A | 3/18/2026 | $80M | $600M | $0.33 | Spark Capital, Transformation Capital, Conviction, McKesson Ventures, General Catalyst, Y Combinator | ||||
 | Moonwalk Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Musely | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $28.08M | Series B | 9/12/2014 | $20M | $117.1M | $12.56 | SharesPost and several undisclosed investors | ||||
 | Neuron23 | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $310.11M | Series D | 6/24/2025 | $96.5M | $331.2M | $0.99 | Westlake Village BioPartners, SoftBank, Redmile Group, Blue Owl, Kleiner Perkins, HBM Healthcare Investments, Acorn Bioventures | ||||
 | nference | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $293.57M | Series C | 12/15/2020 | $62.74M | $858.65M | $7.17 | Matrix Capital Management, Matrix Partners, Mayo Clinic Ventures, NTT Venture Capital | ||||
 | Nimble Rx | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Odyssey Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $413.6M | Series D | 9/10/2025 | $213.63M | $527.3M | $14.62 | Affinity Asset Advisors, Dimension Capital, Jeito Capital, Lightspeed Ventures, TPG, Wedbush Healthcare Partners | ||||
 | Omada Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $444.57M | Series E | 2/23/2022 | $197.55M | $1.01B | $17.99 | Fidelity, aMoon, Perceptive Advisors, Wellington Management, Civilization Ventures | ||||
 | OrsoBio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $166.63M | Series B | 9/6/2024 | $67M | $316.32M | $0.71 | Ascenta Capital, Woodline Partners, Samsara Biocapital, Longitude Capital, Enavate Sciences, NuevaBio, Eli Lilly and Company | ||||
 | Ossium Health | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $35.91M | Series D | 1/27/2026 | $31.31M | $46.46M | $0.23 | Undisclosed Investors | ||||
 | Parse Biosciences | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Plexium | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | PointClickCare | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | restor3d | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $155.97M | Series B-1 | 8/22/2025 | $65M | $265.79M | $2.60 | Partners Group | ||||
 | Semma Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | TRexBio | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $218.62M | Series B | 1/27/2026 | $134.06M | $268.67M | $3.09 | Janus Henderson Investors, Balyasny Asset Management, Affinity Asset Advisors, Delos Capital, Avego BioScience Capital, Agent Capital, Eli Lilly and Company, SV Health Investors, Pfizer Ventures, Johnson & Johnson Innovation, Alexandria Venture Investments, Polaris Partners | ||||
 | TRIANA Biomedicines | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $230.06M | Series B | 12/3/2025 | $120.06M | $262.22M | $3.04 | Ascenta Capital, Bessemer Venture Partners, YK Bioventures, Regeneron Ventures, Invus, Finchley Healthcare Ventures, RA Capital Management, Atlas Venture, Lightspeed Venture Partners, Pfizer Ventures, Surveyor Capital | ||||
 | Turquoise Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $96.49M | Series C | 3/17/2026 | $36.46M | $314.03M | $11.72 | Oak HC/FT, Andreessen Horowitz, Adams Street Partners, Yosemite | ||||
 | Vial | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $109.14M | Series B-2 | 11/30/2022 | $67M | $799.22M | $3.07 | General Catalyst, Byers Capital, BoxGroup | ||||